Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma

Highlight

• Talquetamab, a bispecific antibody targeting GPRC5D, combined with daratumumab, shows enhanced efficacy in relapsed/refractory multiple myeloma (RRMM).
• The phase 1b TRIMM-2 trial reported overall response rates of up to 82.4% with manageable safety in heavily pretreated patients.
• Median progression-free survival exceeded 20 months, indicating durable disease control.
• The combination leverages daratumumab’s immunomodulatory effects to create an environment conducive to talquetamab activity.

Study Background and Disease Burden